We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sudden Death and Staged Therapy for Hemodynamic Stabilization in Patients Enrolled in a Heart Transplantation Program.
- Authors
Frey, Bernhard; Wutte, Michael; Berger, Rudolf; Ioannides, Cleantffls; Hülsmann, Martin; Stanfek, Brigitte; Pacher, Richard
- Abstract
To investigate the impact of staged therapy for advanced heart failure on therapeutic endpoints, 236 consecutive patients (coronary artery disease/dilated cardiomyopathy in 61/175 patients, left ventricular ejection fraction 14% ± 5%, New York Heart Association Class II/III/IV in 102/79/55 patients, respectively) with advanced heart failure were prospectively followed. One hundred thirty-seven patients enrolled from January 1989 to December 1991 were treated conventionally with digoxin, furosemide, and low dose angiotension converting enzyme (ACE) inhibition. Patients refractory to this therapy underwent urgent heart transplantation. Ninety-nine patients enrolled from January 1992 to August 1993 underwent staged therapy: stage 1: maximal tolerated ACE inhibition; stage 2: therapy with PCE-i for pre- and after load reduction to achieve hemodynamic stabilization; or stage 3: refractory patients bridged to heart transplantation with continuous outpatient dobutamine. Sudden death was defined as death within 1 hour of symptoms if heart failure symptoms remained stable over the previous 7 days. Conventionally treated patients were followed for 10 ± 9 months; patients who underwent staged therapy for 9 ± 5 months. In the group of patients that underwent standard therapy, 39 of 137 (28%) patients died: 5 (13%) deaths occurred suddenly, and death due to progressive pump failure occurred in the remaining 34 (87%) patients. In the group of patients that underwent staged therapy, 25 of 99 (25%) patients died; 13 (52%) deaths occurred suddenly, and 12(48%) deaths occurred due to progressive pump failure. Thus, patients who underwent staged therapy were at increased risk for sudden death (P = 0.01. relative risk 3.4, 95% confidence interval 1.2-9.7) but were at lower risk for death from pump failure (P = 0.009. relative risk 0.44, 95% confidence interval 0.22-0.84). In patients who underwent therapy with continuous outpatient PGE-, (n = 7) or dobutamine (n = 21), risk for sudden death (P = NS by log rank test) did not increase. In conclusion, staged therapy significantly reduced death from pump failure; however, patients who could be stabilized and considered too well for heart transplantation were at increased risk for sudden death. Thus, overall survival did not improve. Of note, outpatient dobutamine did not increase the risk for sudden death.
- Subjects
HEART transplant recipients; MORTALITY; SUDDEN death; HEART failure; SURGERY; THERAPEUTICS; CARDIOLOGY
- Publication
Pacing & Clinical Electrophysiology, 1995, Vol 18, Issue 1, p152
- ISSN
0147-8389
- Publication type
Article
- DOI
10.1111/j.1540-8159.1995.tb02495.x